May 6, 2014, 8:30am CDT
Azaya Therapeutics Inc. to collaborate with the University of Chicago
May 6, 2014, 8:30am CDT
Azaya Therapeutics has formed a research partnership with the University of Chicago to test out a new proprietary formulation of docetaxel.
It is continue reading this link soft viagra tabs better to consume the pill with water and in an empty stomach for better effects. However this is another thing that these methods are prone to injuries, bleeding and harm to penile get more levitra properien region. The spedeeprootsmag.org viagra in the usat helps you to re-experience sexual emotions and inter sexual states3. It’s a truism that we live in an era which is seeing (fortunately and unfortunately), some of the greatest and most amazing developments in Science and Technology. http://deeprootsmag.org/author/david-mcgee/page/9/ on line cialis Azaya Therapeutics Inc. has entered into a collaboration with the University of Chicago. Investigators at the university’s Ludwig Center for Metastasis Research will work to develop a new application for Azaya’s investigational drug ATI-1123.
ATI-1123 is a proprietary formulation of the chemotherapy agent docetaxel, commonly known as Taxotere. The San Antonio-based clinical-stage oncology company is seeking to determine whether a low, clinically safe dose of radiation can significantly enhance the delivery of ATI-1123 to experimental tumors in laboratory mice.
The new study, led by Dr. Stephen J. Kron and Dr. Ralph R. Weichselbaum, will also document the effects of radiation on accumulation of docetaxel in the irradiated tumors, and examine whether the combination leads to greater inhibition of tumor growth.
Azaya officials say the work with University of Chicago researchers may serve as a model for future clinical studies in cancer patients undergoing radiation therapy.
“The outcome of this study could lead to a new treatment option for cancer patients, in which our ATI-1123 liposomal docetaxel would provide a powerful means to improve the benefits of radiotherapy,” says Azaya Therapeutics President and CEO Mike Dwyer. “Given the established safety of ATI-1123 on its own, we plan to test this combination in cancer patients if the results of the animal study are promising.”
Over half of all cancer patients receive radiotherapy during the course of their disease. Using the radiation to direct liposomal drugs to tumors could improve the benefits of treatment to these patients,” Azaya officials say.